Sriphal Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 3.56 Cr
as on 15-05-2024
- Paid Up Capital ₹ 0.01 Cr
as on 15-05-2024
- Company Age 8 Year, 8 Months
- Last Filing with ROC 31 Mar 2023
- Revenue %
(FY 2019)
- Profit 100.00%
(FY 2019)
- Ebitda 100.00%
(FY 2019)
- Net Worth -0.00%
(FY 2019)
- Total Assets 79.69%
(FY 2019)
About Sriphal Life Sciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 3.56 Cr and a paid-up capital of Rs 0.01 Cr, as per Ministry of Corporate Affairs (MCA) records.
Koganti Rao, Anand Kanekanti, Surya Nistala, and One other member serve as directors at the Company.
- CIN/LLPIN
U24100AP2016PTC098348
- Company No.
098348
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Feb 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Vijayawada
Industry
Company Details
- Location
Ananthapur, Andhra Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Sriphal Life Sciences?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Koganti Rao  | Director | 17-Feb-2016 | Current |
| Anand Kanekanti | Director | 17-Feb-2016 | Current |
| Surya Nistala | Additional Director | 21-Jun-2019 | Current |
| Venkata Mella | Director | 17-Feb-2016 | Current |
Financial Performance and Corporate Structure Insights of Sriphal Life Sciences.
Sriphal Life Sciences Private Limited, for the financial year ended 2019, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 100% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sriphal Life Sciences?
In 2017, Sriphal Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Hindupur Envirotech Association
Active 6 years 7 monthsKoganti Rao and Venkata Mella are mutual person
Hindupur Industries Association
Active 4 years 1 monthKoganti Rao, Anand Kanekanti and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sriphal Life Sciences?
Unlock and access historical data on people associated with Sriphal Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sriphal Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sriphal Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
